LACTIN-V, also known as CTV-05 or as ''Lactobacillus crispatus'' CTV-05, is a
live biopharmaceutical medication containing a strain of ''
Lactobacillus crispatus'' (''L. crispatus'') which is under development for the treatment of
urinary tract infections (UTIs) and
bacterial vaginosis
Bacterial vaginosis (BV) is a disease of the vagina caused by excessive growth of bacteria. Common symptoms include increased vaginal discharge that often smells like fish. The discharge is usually white or gray in color. Burning with urination ...
(BV).
It is administered
intravaginally and is described as the first
vaginal microbiome
Vaginal flora, vaginal microbiota or vaginal microbiome are the microorganisms that colonize the vagina. They were discovered by the German gynecologist Albert Döderlein in 1892 and are part of the overall human flora.
The amount and type of ...
(VMB)-based
live biotherapeutic product (LBP).
Depletion of
hydrogen peroxide (H
2O
2)-producing ''
Lactobacillus'' strains such as ''Lactobacillus crispatus'' in the
vagina has been strongly associated with BV and UTIs.
Most commercially available
probiotic ''Lactobacillus'' strains are not vaginal strains and do not appear to improve vaginal or urinary health outcomes.
The
Centers for Disease Control and Prevention (CDC)'s ''Sexually Transmitted Infections Treatment Guidelines'' (2021) noted that intravaginal LACTIN-V produced a considerably lower recurrence of BV following initial
antibiotic
An antibiotic is a type of antimicrobial substance active against bacteria. It is the most important type of antibacterial agent for fighting bacterial infections, and antibiotic medications are widely used in the treatment and prevention of ...
treatment with
metronidazole in a
randomized controlled trial.
However, the guidelines also noted that LACTIN-V is not yet
Food and Drug Administration (FDA)-approved or commercially available.
As of December 2021, LACTIN-V is in
phase 2
Michael Lawrence Marrow (August 2, 1955 – December 12, 2019), known as PHASE 2 and Lonny Wood, was an American aerosol paint artist based in New York City. Mostly active in the 1970s, Phase 2 is generally credited with originating the "bubble l ...
/
3 clinical trials for the treatment of UTIs and is in phase 2 trials for the treatment of BV.
It was originated by GyneLogix and is under development by Osel Inc., the
National Institute of Allergy and Infectious Diseases, and other organizations.
References
External links
CTV-05 (LACTIN-V; Lactobacillus crispatus CTV-05) - AdisInsight
Experimental drugs
Lactobacillaceae
Probiotics
{{Genito-urinary-drug-stub